Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma by Gao, Y. et al.
fonc-10-557638 September 24, 2020 Time: 19:47 # 1
ORIGINAL RESEARCH


















†These authors have contributed
equally to this work and share first
authorship
Specialty section:
This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Oncology
Received: 30 April 2020
Accepted: 24 August 2020
Published: 25 September 2020
Citation:
Gao Y, Chen S, Vafaei S and
Zhong X (2020) Tumor-Infiltrating
Immune Cell Signature Predicts
the Prognosis and Chemosensitivity





Signature Predicts the Prognosis and
Chemosensitivity of Patients With
Pancreatic Ductal Adenocarcinoma
Yuzhen Gao1,2†, Shipeng Chen2†, Somayeh Vafaei3* and Xiaoli Zhong1*
1 Department of Molecular Diagnosis, Clinical Medical College, Yangzhou University, Yangzhou, China, 2 Department
of Laboratory Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China, 3 Department of Molecular
Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
Objective: Tumor-infiltrating immune cells might add a predictive value for the
prognostic stratification of patients with pancreatic ductal adenocarcinoma (PDAC) and
chemotherapy response. We aimed to develop a prognostic model based on the tumor-
infiltrating immune cell signature to improve the prediction of survival and chemotherapy
benefits of patients with PDAC.
Methods: The abundance of tumor-infiltrating immune cells for 661 patients with PDAC
from four different cohorts with survival data was collected in the training cohorts. Cox
regression analysis and meta-analysis of immune cells were conducted to generate the
tumor immune cell score (TICS) for prognostic stratification. Other two independent
cohorts including 188 patients were then used to validate the model. Those patients who
underwent chemotherapy were used to further analyze the value of TICS for predicting
the chemotherapy response. Furthermore, the difference in the somatic mutations and
immune-related molecules between the TICS subgroups was analyzed.
Results: 6 out of 28 immune cells were found to be significantly associated with PDAC
prognosis in the training cohorts (all P < 0.05). The developed TICS could significantly
predict the PDAC survival and chemotherapy benefit both in the training and the external
validation cohorts (log-rank test, P < 0.05). Significant differences were found in different
TICS subgroups in terms of the immune characteristics, checkpoint genes, and tumor
mutational burden. Functional and pathway analyses further proved that the TICS was
significantly related to the tumor immunity response in patients with PDAC.
Conclusion: TICS might be used to predict PDAC patients with a better survival and
greater chemotherapy benefit.
Keywords: pancreatic ductal adenocarcinoma, immune cell, prognosis, chemotherapy response, signature
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths
worldwide and it consists of almost 90% pancreatic cancers (1, 2). Although in recent years
significant improvements have been achieved in the diagnosis and treatment of different kinds
of cancers (3), the mortality rate of PDAC has not experienced substantial changes during the
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past decades. This is because PDAC is a highly destructive cancer
with an extraordinarily high malignancy and a particularly poor
prognosis (4). Once this aggressive cancer is diagnosed, the 5-
year survival rate is only around 7%, and the 1-year survival
rate is <20% (5). Surgery is the first option for the resected
stage of PDAC and adjuvant chemotherapy is the standard
treatment following surgery. Numerous studies have shown that
patients’ long-term survival improved after the treatment with
adjuvant chemotherapy (6). However, given its poor prognosis
among cancer and despite combining the advances in surgical
techniques and other adjuvant therapy in recent years, the tumor
recurrence rate remains at 80% (6). Currently, the prognostic
stratification of a resected PDAC is based on the 8th edition
of the AJCC–TNM classification (7), which mostly relies on
the tumor invasion parameters containing tumor burden (T),
the influence of cancer cells in lymph nodes (N), and presence
of metastases (M). However, the differences persist in the
individual tumor biology and immune cell characteristics among
patients suggesting the weakness of the current prognostic system
(8). Thus, the effective and accurate stratification of patients
with PDAC for prognosis and chemotherapy response is of
great importance.
Although aggressive PDAC renders the development of
novel prognosis prediction challenges in current oncological
research (9), immune cells within the tumor microenvironment
(TME) contribute to the prognostic assessment in a wide
range of malignancies (10–12). Highly infiltrated T-lymphocytes,
especially CD8+ T cells in TME, are associated with a
good overall survival (OS) and disease-free survival (DFS).
By contrast, patients with a large amount of immune-
suppressive cells, such as myeloid-derived suppressor cells
(MDSCs), M2 macrophages, and CD4+CD25+Fop3+ Tregs,
show a relatively poor outcome because of the block of the
cytotoxic T-cell function in the recognition and clearance
of cancer cells (13–15). Based on the effect of the tumor-
infiltrating immune cells on patients’ prognosis (16), we then
questioned whether the features of immune cells benefit
the prediction of prognosis and chemotherapy response of
PDAC. Thus, the current study aimed to analyze the tumor-
infiltrating immune cells to establish a tumor immune cell
score (TICS) in order to enhance the prediction of prognosis
and chemotherapy response of patients with PDAC. To the
best of our knowledge, this study is the first to focus on
predicting the survival and chemotherapy treatment responses
of patients with PDAC based on the tumor-infiltrating immune
cell signatures.
A total of 849 PDAC patients with a detailed medical
information were collected from The Cancer Genome Atlas
program (TCGA), International Cancer Genome Consortium
(ICGC), and Gene Expression Omnibus (GEO) databases.
Bioinformatics analysis–based immune cell-specific signatures
were applied to characterize the composition of tumor-
infiltrating immune cells and immune-related molecules (17).
To avoid bias, the prognostic immune cell signatures were
selected based on a meta-analysis from the four different
clinical cohorts (18). TICS was developed systematically
for predicting the survival and treatment response from
adjuvant chemotherapy by taking advantage of the tumor-
infiltrating immune cell signatures. The significant differences
in the clinical characteristics, immune molecules, and tumor
mutational burden (TMB) between the high/low TICS subgroups
were observed. Furthermore, these results were validated
in the two external patient cohorts. High TICS can predict
PDAC patients with better survival outcomes and classify




All the PDAC transcriptome and clinical data were obtained
from the TCGA, ICGC, and GEO databases. Four different
cohorts including the TCGA-PAAD-US (n = 146), ICGC-
PACA-AU (n = 267), ICGC-PACA-CA (n = 182), and
GSE62452 (n = 66) were enrolled as the training cohorts.
Two other independent cohorts: GSE71729 (n = 125) and
GSE57495 (n = 63), were utilized as the external validation
cohorts (Supplementary Table S1). The corresponding somatic
mutation data of the enrolled patients were also downloaded
from the databases above. All the expression data were
normalized, the raw files were applied in the Robust Multi-
array Average (RMA) algorithm, and the background adjustment
using the “affy” and “simpleaffy” software package. Besides,
log2 transform was applied in this analysis. The pan-cancer
cohorts from the GDC Pan-Cancer in the UCSC Public
Hub were also downloaded for further analysis in the
present study1.
Calculation of Tumor-Infiltrating Immune
Cells, Tumor Mutation Burden, Immune
Score, and Cytolytic Activity Score
The single sample gene set enrichment analysis (ssGSEA)
algorithm was used to quantify the relative abundance of the
tumor-infiltrating immune cells of patients with PDAC. Seven
hundred eighty-two (782) immune genes were obtained based
on the previous research (18). These associated genes could
be assessed via the package of the “GSVA” in Bioconductor
before the treatment schedule. TMB was defined as the
number of somatic mutations in the coding region per
megabase including the single nucleotide variants (SNVs)
and small insertions and deletions (Indels). ImmuneScore
was developed by using the “ESTIMATE” packages in each
patient (19). Furthermore, the cytolytic activity (CYT)
score as the geometric mean of granzymes A (GZMA) and





Cox proportional hazards regression analysis was conducted to
explore the prognostic evaluation of 28 immune cells. Each
1https://xenabrowser.net/datapages/
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immune cell was stratified by the median value into two groups
in the four PDAC training cohorts. The pooled hazard ratio (HR)
with a 95% CI of each immune cell was estimated by using the
fixed-effects model based on meta-analysis. With the immune
cells, the pooled HRs with their standard estimates (SE), which
were significantly related to prognosis, were then integrated as
the prognostic immune cell weight and generated the TICS. In







where GSVA (cell) is the relative infiltration of the OS-related
immune cells by GSVA and n is the number of the OS-related
immune cells based on the meta-analysis. In our analyses, the
normalized Z-score was used to calculate the score. The best cut-
off values of TICS in the different cohorts were truncated by the
“survminer” package in the R software.
Functional and Pathway Enrichment
Analysis
The present study also aimed to investigate the potential
difference in the biological function between the different TICS
subgroups. A total of 96 immune-related gene sets of functional
annotations were downloaded from the “msigdb.v7.0.symbols”
in the MSigDB. The up- and down-regulated immune-
related terms between the different TICS subgroups were
identified by running the “pathifier” R package in the TCGA
transcripts. Gene Ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) functional annotations using
the “clusterProfiler” R package were performed based on the
alternating TICS signature genes. Enrichment P-values were
based on 1,000 permutations and subsequently adjusted for
multiple testing using the Benjamini–Hochberg procedure to
control the FDR.
Statistical Analysis
Statistical analysis of all the clinical data was performed in R
3.6.2 – standard tests including the Student’s t-test, Wilcoxon
rank-sum test, and Fisher exact test. The method of Benjamini–
Hochberg, which is the same as the FDR in R, was also
used to adjust the P-values for multiple comparisons. The
relationship between TICS and other continuous variables was
calculated by the Spearman method. The optimal cutoff values
of TICS and TMB were selected by using the “survminer” R
package. The log-rank test and univariate and multivariate cox
proportional hazard regression was used to explore the related
independent predictors of the prognosis. Additionally, time-ROC
was used to detect the prognostic value of TICS and other
variables for the prognosis of PDAC patients. The area under
the receiver operating characteristic curve (ROC) was used to
detect the diagnostic value of TICS for chemosensitivity. All
reported P-values were two-sided, and the statistical significance
was set at 0.05.
RESULTS
Large-Scale Meta-Analysis Reveals the
Prognostic Value of Tumor-Infiltrating
Immune Cells in PDAC
A schematic of the study design and model development
is shown in Figure 1. Overall survival (OS) analysis of the
661 patients in the four training cohorts (TCGA-PAAD-US,
ICGC-PACA-AU, ICGC-PACA-CA, and GSE62452) and the 188
patients in the two validation cohorts (GSE71729 and GSE57495)
showed no significant differences (Supplementary Figure S1).
The landscape of the 28 infiltrated immune cells including the
adaptive immune cells and innate immune cells was generated
based on the mRNA expression in each cohort, respectively.
Strong relationships among the 28 immune cells were observed
in the training cohorts (Figure 2A, P < 0.05). We conducted
a prognostic analysis for the 28 immune cells in each training
cohort and performed a meta-analysis to obtain these stable
and pooled hazard ratio (HR) and coefficients of all 28 immune
cells (Supplementary Table S2). In brief, the activated CD4 T
cells and neutrophils were risk factors (all HR > 1, P < 0.05),
while monocytes, activated B cells, macrophages, and Th17 were
protective factors for the prognosis in patients with PDAC (all
HR < 1, P < 0.05) (Figure 2B).
Establishment of TICS Based on the
Selected Prognostic Tumor-Infiltrating
Immune Cells
We established TICS for each patient based on the relative
abundance of the six selected tumor-infiltrating immune cells
(21). TICS had a better predicting capacity than any other of the
six single immune cell alone for predicting survival through the
time-dependent-ROC analysis in the training cohorts (Figure 2C,
all P < 0.05). We also found that the expression levels of the
activated B cells, monocytes, macrophages, and Th17 cells were
positively related to the TICS while the activated CD4 T cells
and neutrophil cells showed a negative relationship with the TICS
(Figure 2D, all P < 0.001). All the patients in the training cohorts
were then divided into two subgroups based on the best cutoff
value of the TICS: the high TICS subgroup (n = 419) and the low
TICS subgroup (n = 242), and a significantly different prognosis
was observed (log-rank test, P < 0.001; Figure 2E).
Prognosis Analysis of TICS in the
Training, Validation, and Pan-Cancer
Cohorts
To detect the prognostic value of TICS in PDAC patients, we used
the univariate and multivariate cox regression analyses to explore
the risk factors for the OS of patients with PDAC in all cohorts
(Supplementary Table S4). The multivariate analysis showed
that only the TICS was considered as a protected prognostic
factor of OS in the training cohorts (Figure 3A, P < 0.05).
Fortunately, this conclusion also could be validated in the other
two validation cohorts (Figure 3A, P < 0.05). According to the
KM curves, we found that the TICS could easily distinguish the
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FIGURE 1 | A schematic of the study design and model development. Details of the study design and PDAC patients cohorts classification for model training and
validation in regards to the overall survival, immune and tumor characterization, as well as the chemosensitivity prediction.
PDAC patients with different prognosis in all four training and
two external cohorts, respectively (Figures 3B–G, P < 0.05).
Furthermore, TICS was significantly related with the recurrence-
free survival rate in the TCGA-PAAD and ICGC-PACA-AU
cohorts (Figures 3H,I, P = 0.0012 and 0.00018, respectively).
Lastly, we validated TICS for the prognosis of pan-cancers and
the results showed that TICS could also significantly distinguish
the prognosis of 9/32 cancers. The details of Pan-cancer analysis
could be found in Figure 3J and Supplementary Table S5.
To summarize, the statistically significant prognostic differences
were observed in all the PDAC cohorts and some of the pan-
cancer cohorts based on the TICS subgroups.
Characteristics of Clinical Factors,
Immune Molecules, and Immune
Function Based on TICS
The patients in the TCGA group (n = 146) were divided into high
and low TICS subgroups. To explore the potential difference of
immune status between patients in the TICS subgroups, immune
checkpoints, chemokines, and major histocompatibility complex
(MHC) genes were collected and analyzed based on the TCGA
cohort (Figure 4A). The P-values of different comparisons of
these representative genes between the two groups were adjusted
by the method of Benjamini–Hochberg procedure. In particular,
some immune checkpoint genes, such as PDCD1LG2(PD-L2),
PDCD1(PD1), CTLA4, LAG3, and HAVCR2 have a relative
high expression in the high TICS subgroup than the low
TICS subgroup (Figure 4A, all P < 0.05), except CD274(PD-
L1) (P > 0.05). Conversely, among the chemokines, only
CXCL9 showed a higher expression in the high TICS subgroup
(Figure 4A, P = 0.007). For the clinical characteristics, there
is no significant correlation between the TICS subgroup and
clinical parameters in the TCGA cohort (Figure 4A). Besides,
there is also no significant difference in the prognosis based on
the clinical TNM stage systems (I–II vs. III–IV) (Supplementary
Figure S2), however, the TICS could distinguish the prognosis of
PDAC within the TNM stage I–II and III–IV (Figure 4B, both
p < 0.001). Furthermore, the TICS cores was strongly associated
to both the CYC and ImmuneScore (Figure 4C, P < 0.001). The
strong relationship between the TICS and CYC/ImmuneScore
in other patient cohorts is demonstrated in the Supplementary
Figure S3 (all P < 0.001).
After analyzing 96 immune-related gene sets for the patients
in the TCGA cohort, 76 of them showed significant differences
between the TICS subgroups. Among them, 51 out of 76
immune-related gene sets were up-regulated and 25 out of 76
immune-related genes were down-regulated in the high TICS
group (Supplementary Table S6 and Figure 4D). It indicated
that our TICS was a prognostic score which significantly related
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FIGURE 2 | Establishment of Tumor-infiltrating immune cell score (TICS). (A) The spearman relationship within the 28 immune cells. (B) Forest plot for the prognostic
values of the 28 immune cells in PDAC patients; (C) Time-dependent receiver operating characteristic curve (ROC) analysis of the six prognostic immune cells and
TICS. (D) The differences of the six prognostic immune cells between the high and low TICS subgroups which stratified by the best cut-off value. (E) The
Kaplan-Meier curve of the TICS subgroups in total PDAC patients.
to the immune status of patients with PDAC. Besides, immune-
related pathways of the B cell receptor signaling pathway,
cell adhesion molecules, and Th17 cell differentiation have a
higher enrichment in high TICS patients in the TCGA cohort
(Figure 4E). Other results of immune-related GO and KEGG
terms are shown in Supplementary Tables S7, S8.
PDAC Somatic Genome Characteristics
of the TICS Subgroups
The somatic mutations of the TCGA patients (n = 115) were
integrated for further TMB analysis. The unique TMB score
can indicate a low prevalence of somatic mutations. First, the
relationship between the TICS and TMB was explored here. The
scatter plot showed that TICS was negatively related to TMB
scores (Figure 5A, r = −0.278, P = 0.001). Besides, patients
with a high TMB showed a statistically worse overall survival
(Figure 5B, p < 0.05). The same negative association could
also be found in ICGC-PACA-AU (Supplementary Figure S4,
P < 0.001). Notably, the combination of the TMB scores and
TICS improved the prediction of the PDAC prognosis. The low
TMB and high TICS groups showed the best prognosis compared
with the other groups while the high TMB and low TICS groups
had the worst prognosis (Figure 5C, p < 0.05). The difference
in the mutated genes were also studied between the high TICS
and low TICS groups (Figures 5D,E). Of note, the percentage of
KRAS in the high TICS cohort were lower than that in the low
TICS cohort (chi-square test, P< 0.05). In particular, a significant
difference between the TMB genes among the different TICS
cohorts was observed.
Utilization of TICS for Chemosensitivity
Prediction
On the basis of the clinical information in the TCGA
and ICGC-PACA-CA cohorts, we found that 88 and 106
patients with matching the information of chemotherapy,
respectively. First, the immune cells, immune-related genes,
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FIGURE 3 | Prognostic analysis of TICS model in the training cohorts and validation cohorts. (A) Prognosis analysis of TICS in all PDAC cohorts (High vs. Low TICS).
Kaplan–Meier survival curve of the overall survival (OS) in PDAC patients with high TICS and low TICS in TCGA-PAAD-US (n = 146) (B), ICGC-PACA-CA (n = 182)
(C), ICGC-PACA-AU (n = 267) (D), GSE62452 (n = 66) (E), GSE71729 (n = 125) (F), and GSE57495 (n = 63) (G). Kaplan–Meier survival curve of recurrence-free
survival in PDAC patients with high TICS and low TICS in TCGA-PAAD-US (n = 146) (H), and ICGC-PACA-AU (n = 267) (I). (J) Prognosis analysis of TICS in
Pan-Cancers (High vs. Low TICS).
and clinical characteristics were compared between patients
with a complete response (CR) and non-CR status in the
two abovementioned cohorts. The results demonstrated that
only TICS (P = 0.004) and ImmuneScore (P = 0.014) showed
significant differences between the CR and non-CR groups
in TCGA. Furthermore, patients with CR showed a higher
tendency in the immune-related genes and immune cells,
although, only some of them showed statistically significance
(Figure 6A). Similar results were also documented in the ICGC-
PACA-CA cohort and it was even more obvious that the CR
patients have a higher abundance of immune cells and immune
gene expression (Supplementary Figure S5). Chemotherapy
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FIGURE 4 | Characteristics of clinical factors, immune molecules and immune function based on TICS. This figure refers to the TCGA cohort (n = 146). (A) Specify
immune checkpoints, chemokines, MHC, and clinical characteristics of the TICS subgroups. (B) The prognosis of the combination of TICS and TNM stages. (C) The
correlation between the TICS and ImmuneScore/CYT. (D) TICS distinguishing Immune-related terms from the “msigdb.v7.0.symbols” in MSigDB; (E) GSEA of KEGG
analysis between TICS subgroups.
significantly improved the prognosis of patients with PDAC
compared with those without chemotherapy (Figures 6B,C, log-
rank test, P < 0.001).
Intriguing, TICS could significantly distinguish the prognosis
of the PDAC patients with chemotherapy, but not in the
patients without chemotherapy (Supplementary Figure S6).
Besides, we found 50% and 90% patients in the high
TICS subgroup with a CR status in the TCGA and ICGC-
PACA-CA cohorts, respectively; meanwhile, the low TICS
group showed a much smaller percentage of CR patients
in both cohorts (Figure 6D, TCGA, P = 0.002; Figure 6F,
ICGC-PACA-CA, P < 0.001). Besides, patients with CR had
the highest TICS both in the TCGA and ICGC-PACA-CA
cohorts (Figure 6E, P = 0.011 and Figure 6G, P = 0.005).
However, TMB was not significantly related to the different
chemotherapy responses in both cohorts (Supplementary
Figure S7). We combined TICS with ImmuneScore to predict the
CR status of patients with PDAC who received chemotherapy.
The combined scores achieved the best prediction for CR
in both cohorts compared with these two scores alone
(Figure 6H, TCGA, AUC = 0.710; Figure 6I, ICGC-PACA-
CA, AUC = 0.780).
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FIGURE 5 | PDAC somatic genome characteristics of TICS subgroups. This figure refers to the TCGA cohort (n = 146). (A) Correlation of TICS and Tumor mutation
burden (TMB). (B) Prognosis analysis between the low TMB and high TMB patients. (C) The prognosis analysis of the combination of TICS and TMB subgroups.
(D,E) The difference of most frequent mutations genes in high TICS and low TICS subgroups, respectively.
DISCUSSION
Pancreatic ductal adenocarcinoma is a highly devastating cancer
with a particularly poor prognosis. Late and inefficient diagnosis
and aggressive cancer biology largely determine the unfavorable
outcomes of PDAC. Adjuvant systemic chemotherapy works as
the first-line postoperative treatment to strive for a long-term
survival (22). Thus, a highly accurate prognostic assessment
and chemotherapy response prediction of PDAC are crucial
for individualized surveillance plans and clinical decisions.
Therefore, this study aimed to identify a particular immune
cell pattern based on the biological features of individual
tumors to better categorize patients into different prognostic
subgroups and identify patients who could reach a greater
benefit from the adjuvant chemotherapy. At present, some
other immune indicators such as ESTIMATE score (19) and
Golon’s ImmuneScore (23) mainly focus on the description of
suppressive immune environment characteristics. We know that
even though the immune microenvironment of each tumor
is similar, its prognosis is not completely consistent with the
state of the immune environment. Methods such as TIMER
and CIBERSORT are based on the relative expression of cells
obtained by analyzing the data expression of the reference queue.
The heterogeneity of the tumor caused the reference cohort
to not completely conform the actual patient situation but the
ssGSEA method provides a stable production route without such
shortcomings. TICS has a good generalization ability for multiple
PDAC tumors, which is an advantage other scores do not have.
Besides, TICS integrates OS and immune microenvironment
characteristics and corrects the prognostic coefficient of OS for
the equivalent expression of tumor-infiltrating immune cells.
In the present study, we developed a novel immune score
that predicts the survival and chemosensitivity of PDAC. Among
these cells that significantly associated with the prognosis in our
study, neutrophils and CD4+ T cells are negatively correlated
with the TICS. It is widely accepted that the majority of pancreatic
cancers arise from the context of chronic inflammation (21).
Neutrophil and CD4+ cells, as the major inflammatory cells,
might increase the risk of carcinogenesis and tumor progression
of pancreatic cancer. This belief is fueled, in part, by the fact
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FIGURE 6 | The Utilization of TICS for Chemosensitivity Prediction. These figures refer to the TCGA (n = 88) and ICGC-PACA-CA cohorts (n = 106). (A) Heatmap of
the immune cells and immune related genes between the patients with status CR and non-CR after chemotherapy. (B,C) Survival analysis for patients with and
without chemotherapy in TCGA and ICGC cohorts, respectively. (D,E) Bar and box plot for the relationship between TICS and chemosensitivity in the TCGA cohort.
Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD). (F,G) Bar and box plot for the relationship between TICS and
chemosensitivity in the ICGC-PACA-CA cohort. (H,I) ROC analysis of TICS and the combination with other immune-related genes for predicting the complete
response status in both cohorts.
that the peripheral elevated tumor-infiltrating neutrophils in
PDAC patients predict worse clinical outcomes (24). Of note,
the CD8+ T cells does not included in the TICS, although the
infiltrating cytotoxic T cells are associated with the efficacy of
the immunotherapy, the fate of these effector cells is largely
dependent on the TME (25). The immunosuppressive tumor
microenvironment of PDAC might exhaust the infiltrating CD8+
T cells (26). In light of this point, it is important to characterize
the immune subsets which might shape the pro-tumor and anti-
tumor effects of the PDAC microenvironment. Nevertheless, the
analysis revealed that the number of monocytes and macrophages
in the tumor tissue associates with a better overall survival. It
contrasts with the view that the tumor-associated macrophages
suppress the immune response in PDAC. But the impact of
macrophages on tumor progression cannot be easily determined
as the macrophages have two faces inside the tumor: M1: anti-
tumor and M2: pro-tumor. Recently, Weissman’s study has
revealed that the macrophage might phagocyte the tumor cells
as the innate immune cells (27). The dual roles of macrophages
warrant further investigation in the PDAC. Similarly, the Th17
cells also work as double-edged swords in pancreatic cancers.
Several lines of evidence have shown that the Th17 cells promote
the cytotoxic T cell activation by improving the dendritic cells’
presentation of tumor antigens. Besides, the transplantation
of Th17 T cell in the murine model of pancreatic cancer
has the anti-tumor effect and increases the survival (28). The
above findings elucidate the influence of immune cells in the
improved PDAC prognosis.
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Furthermore, the immune molecules, tumor, and clinical
characteristics of the high and low TICS groups were also
compared. The results showed many differences in immune
characteristics but no significant difference in the clinical
indicators. GSEA of KEGG analysis further reported differences
in the immune signaling pathways between the high and low
TICS patients. Therefore, the TICS staging system demonstrated
a high superiority in classifying patients with PDAC in terms
of the tumor immune biology. Besides, TMB has emerged as
a promising novel biomarker in predicting the prognosis and
immune response in various cancers (29). We discovered that
high mutation rates were associated with genes (KARS and
TP53) (30), which were mostly related to cancer progress, tumor
angiogenesis, and metastasis (31–33). TICS showed a modest
negative relationship with the TMB score (r = −0.28, p < 0.05).
It is reasonable given the relative high immune cells contributing
to the TICS value and result in low TMB. Besides, it also indicates
our mRNA–based immune cell signatures could also reflect the
tumor DNA somatic mutations. Although the TMB score could
also distinguish patients with PDAC into a different prognosis,
TICS was superior to TMB and could further stratify patients with
the similar TMB scores into different subgroups.
In addition, tumor-infiltrating immune cells in the complex
TME were used to predict the chemotherapy response. There
were more patients with a CR status in the high TICS
subgroup than in the low TICS subgroup. Patients with a CR
status had a relatively higher TICS indicating the preexisting
stronger immune ability of the patients achieved CR after
chemotherapy. More intriguing, for patients with chemotherapy,
it is documented that the high TICS patients achieved a
statistically significant survival than the low TICS patients
but not for patients without chemotherapy. This could be
explained that chemotherapy can enhance the tumor antigen
presentation by upregulating the expression of the tumor
antigens themselves (34). Besides, the chemotherapy could also
induce the breakdown of the cancer cells to increase the
level of the tumor-associated antigen available to the antigen-
presenting cells (35). In conclusion, these results revealed
that the immune cell signature could help to predict the
chemotherapy response.
Although our study could add more benefits for predicting
the prognosis and chemotherapy of PDAC, it still has some
limitations. First, we examined the cellular gene expression of 28
common immune cells that appear commonly in the TME but
other types of immune cells within TME should also be included
in future research. Second, both cancer cells and stromal cells
orchestrate tumor-associated inflammation, tumor progression,
and treatment response. Therefore, for a more comprehensive
analysis of the TME, future research should include more
immune cells and consider stromal cells in the TME.
CONCLUSION
In conclusion, our findings revealed that the tumor-infiltrating
immune cell signature can stratify patients with PDAC into
subgroups with different survival outcomes. These signatures
could also be used for identifying the patients that might achieve
a greater benefit from the adjuvant chemotherapy. The TICS
might be applied as an adjunct individualized surveillance tool
to support the TNM prognostic staging system in terms of
cancer immunology.
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